New medications for heart failure

Trends in Cardiovascular Medicine

Volumn 26, Issue 6, 2016, Pages 485-492

  Gordin, Jonathan S ^a   Fonarow, Gregg C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Funny channel; Heart failure therapies; Ivabradine; Neprilysin; Sacubitril valsartan

Indexed keywords

IVABRADINE; MEMBRANE METALLOENDOPEPTIDASE; SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BENZAZEPINE DERIVATIVE; CYCLIC NUCLEOTIDE GATED CHANNEL; PROTEINASE INHIBITOR; TETRAZOLE DERIVATIVE;

CARDIOVASCULAR MORTALITY; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; HEART EJECTION FRACTION; HEART FAILURE; HEART RATE; HUMAN; META ANALYSIS (TOPIC); MORBIDITY; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANTAGONISTS AND INHIBITORS; CONVALESCENCE; DRUG EFFECTS; HEART STROKE VOLUME; METABOLISM; MORTALITY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

AMINOBUTYRATES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTI-ARRHYTHMIA AGENTS; BENZAZEPINES; CYCLIC NUCLEOTIDE-GATED CATION CHANNELS; HEART FAILURE; HEART RATE; HUMANS; NEPRILYSIN; PRACTICE GUIDELINES AS TOPIC; PROTEASE INHIBITORS; RECOVERY OF FUNCTION; SIGNAL TRANSDUCTION; STROKE VOLUME; TETRAZOLES; TREATMENT OUTCOME;

EID: 84962106603     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2016.02.008     Document Type: Review

References (40)

1. [1] Go, A.S., Mozaffarian, D., Roger, V.L., Benjamin, E.J., Berry, J.D., Borden, W.B., et al. AHA statistical update. Heart disease and stroke statistics—2013 update. A report from the American Heart Association. Circulation 127 (2013), e6–e245.
2. [2] Heidenreich, P.A., Trogdon, J.G., Khavjou, O.A., Butler, J., Dracup, K., Ezekowitz, M.D., et al. AHA policy statement. Forecasting the future of cardiovascular disease in the United States. A policy statement from the American Heart Association. Circulation 123 (2011), 933–944.
3. [3] MERIT-HF Study Group, Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet 353 (1999), 2001–2007.
4. [4] Packer, M., Fowler, M.B., Roecker, E.B., Coats, A.J.S., Katus, H.A., Krum, H., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survical (COPERNICUS) study. Circulation 106 (2002), 2194–2199.
5. [5] The Consensus Trial Study Group, Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 316 (1987), 1429–1435.
6. [6] The SOLVD Investigators, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991), 293–302.
7. [7] Pitt, B., Zannad, F., Remme, W.J., Cody, R., Castaigne, A., Perez, A., et al. The effects of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999), 709–717.
8. [8] Swedberg, K., Komajda, M., Bohm, M., Borer, J.S., Ford, I., Dubost-Brama, A., et al. Ivabradine and Outcomes in Chronic Heart Failure (SHIFT): a randomised placebo-controlled study. Lancet 376 (2010), 875–885.
9. [9] McMurray, J.J.V., Packer, M., Desai, A.S., Gong, J., Lefkowitz, M.P., Rizkala, A.R., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
10. [10] Ma, T.K.W., Kam, K.K.H., Yan, B.P., Lam, Y., Renin–angiotensin–aldosterone system blockade for cardiovascular disease: current status. Br J Pharmacol 160 (2010), 1273–1292.
11. [11] Lymperopoulous, A., Rengo, G., Koch, W.J., Adrenergic nervous sytem in heart failure: pathophysiology and therapy. Circ Res 113 (2013), 739–753.
12. [12] Cohn, J.N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325 (1991), 303–310.
13. [13] Banka, G., Heidenreich, P.A., Fonarow, G.C., Incremental cost-effectiveness of guideline-directed medical therapies for heart failure. J Am Coll Cardiol 61 (2013), 1440–1446.
14. [14] Ho, J.F., Larson, M.G., Ghorbani, A., Cheng, S., Coglianese, E.E., Vasan, R.S., et al. Long-term cardiovascular risks associated with an elevated heart rate: the Framingham heart study. J Am Heart Assoc, 3, 2014, e000668.
15. [15] Fragasso, G., De Cobelli, F., Spoladore, R., Esposito, Salerno, A., Calori, G., et al. Resting cardiac energy metabolism is inversely associated with heart rate in healthy young men. Am Heart J 162 (2011), 136–141.
16. [16] Fiuzat, M., Wojdyla, D., PIna, I., Adams, K., Whellan, D., O'Connor, C.M., Heart rate or beta-blocker dose? Association with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACITON trial. J Am Coll Cardiol Heart Fail 4 (2016), 109–115.
17. [17] Poole-Wilson, P.A., Swedberg, K., Cleland, J.G.F., Di Lenarda, A., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 (2003), 7–13.
18. [18] McAlister, F.A., Wiebe, N., Ezekowtiz, J.A., Leung, A.A., Armstrong, PW, Meta-analysis: β-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 150 (2009), 784–794.
19. [19] Triposkiadis, F., Karayannis, G., Giamouzis, G., Skoularigis, J., Louridas, G., Butler, J., The sympathetic nervous system in heart failure: physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 54 (2009), 1747–1762.
20. [20] DiFrancesco, D., The role of the funny current in pacemaker activity. Circ Res 106 (2010), 434–446.
21. f current and its inhibition by heart rate-reducing agents. Curr Med Res Opin 21 (2005), 1115–1122.
22. [22] Fox, K., Ford, I., Steg, P.G., Tendera, M., Ferrari, R., BEAUTIFUL Investigators. Ivabradine for Patients With Stable Coronary Artery Disease and Left-Ventricular Systolic Dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008), 807–816.
23. [23] Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E., Drazner, M.H., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation 128 (2013), e240–e327.
24. [24] Swedberg, K., Komajda, M., Bohm, M., Borer, J., Robertson, M., Tavazzi, L., et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?. J Am Coll Cardiol 59 (2012), 1938–1945.
25. [25] Bohm, M., Swedberg, K., Komajda, M., Borer, J.S., Ford, I., Dubost-Brama, A., et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376 (2010), 886–894.
26. [26] Fox, K., Ford, I., Steg, P.G., Tardif, J., et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 371 (2014), 1091–1099.
27. [27] Tardif, J., O'Meara, E., Komajda, M., Bohm, M., Borer, J.S., Ford, I., et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodeling and function: results from the SHIFT echocardiography substudy. Eur Heart J 32 (2011), 2507–2515.
28. [28] Ekman, I., Chassany, O., Komajda, M., Bohm, M., Borer, J.S., Ford, I., et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J 32 (2011), 2395–2404.
29. [29] Rademaker, M.T., Charles, C.J., Espiner, E.A., Nicholls, G., Richards, A.M., Long-term adrenomedullin administration in experimental heart failure. Hypertension 40 (2002), 667–672.
30. [30] Abassi, Z., Karram, T., Ellaham, S., Winaver, J., Hoffman, A., Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacol Ther 102 (2004), 223–241.
31. [31] Cheng, C., Onishi, K., Ohte, N., Suzuki, M., Little, W., Function effects of endogenous bradykinin in congestive heart failure. J Am Coll Cardiol 31 (1998), 1679–1686.
32. [32] Packer, M., Califf, R.M., Konstam, M.A., Krum, H., McMurray, J.J., Roleau, J., et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Ompapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106 (2002), 920–926.
33. [33] Kostis, J.B., Packer, M., Black, H.R., Schmieder, R., Henry, D., Levy, E., Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 17 (2004), 103–111.
34. [34] Gu, J., Noe, A., Chandra, P., Al-Fayoumi, S., Lingueros-Saylan, M., Sarangapani, R., et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 50 (2010), 401–414.
35. [35] Heran, B.S., Musini, V.M., Bassett, K., Taylor, R.S., Weight, J.M., Angiotensin receptor blockers for heart failure (review). Cochrane Database Syst Rev, 2012 [Art No.: CD003040].
36. [36] Cohn, J.N., Tognoni, G., for the Valsartan Heart Failure Trial Investigators, A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001), 1667–1675.
37. [37] Pablos-Mendez, A., Barr, G., Shea, A., Run-in periods in randomized trials: implications for the application of results in clinical practice. J Am Med Assoc 279 (1998), 222–225.
38. [38] Packer, M., McMurray, J.J., Desai, A.S., Gong, J., Lefkowitz, M.P., Rizkala, A.R., et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131 (2005), 54–61.
39. [39] Logeart, D., Thabut, G., Jourdain, P., Chavelas, C., Beyne, P., Beauvais, F., et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 43 (2004), 635–641.
40. [40] Solomon, S.D., Zile, M., Pieske, B., Voors, A., Shah, A., Kraigher-Krainer, E., et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomized controlled trial. Lancet 380 (2012), 1387–1395.